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The relationship between panic disorder and nonpsychiatric medical illness is complex,
but some evidence suggests that panic disorder increases risk for a variety of nonpsychiatric medical conditions. Given the demonstrated efficacy of cognitive behavioral therapy (CBT) for panic disorder, we were interested in evaluating the effects of CBT for
panic disorder on nonpsychiatric medical symptoms among these patients. Patients were
randomized to a 12-week group-administered CBT protocol (n = 22) or a delayedtreatment conlrol (n = 24). Treated patients showed marked improvement in both anxiety symptoms and physical health symptom ratings that were evident at midtreatment
and were maintained through a 6-month follow-up period. Despite comparable rates
of change, changes in anxiety symptoms did not appear to mediate the relationship between treatment and improved physical health ratings. These findings indicate that
CBT appears to have an immediate and long-term beneficial impact on physical
health and that this effect is independent from its impact on anxiety symptoms.
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Epidemiological reports indicate that a variety of medical conditions are
more prevalent in those with a lifetime history of an anxiety disorder (Wells,
Golding, & Burnam, 1989). Panic disorder in particular is frequently complicated by the presence of nonpsychiatric medical conditions. The association between panic disorder and cardiorespiratory disorders such as asthma,
chronic obstructive pulmonary disease, and mitral valve prolapse is well
established (Gorman et al., 1988; Karajgi, Rifkin, Doddi, & Kolli, 1990;
Weissman, Markowitz, Ouellette, Greenwald, & Kahn, 1990; Zandbergen et
al., 1991).
The relationship between panic disorder and nonpsychiatric medical illness is complex. It appears that nonpsychiatric medical conditions can contribute to the development of panic disorder (Kahn, Drusin, & Klein, 1987;
Raj, Corvea, & Dagon, 1993) and/or exacerbate panic disorder symptoms
(McCue & McCue, 1984). In addition, increasing evidence suggests that panic
disorder can contribute to the development of physical conditions and/or
exacerbate existing physical conditions (Karajgi et al., 1990; Kawachi et al.,
1994). For example, longitudinal evaluation of panic disorder indicates an
increased risk for a number of medical conditions (e.g., hypertension, migraine
headaches, ulcer, thyroid disease) compared to patients with other anxiety
conditions and the general population (Rogers et al., 1994).
The effect of stress on the immune system is one possible pathway to
explain the relationship between anxiety and physical health. Stress is frequently associated with changes in immune parameters (Cacioppo, 1993;
Glaser et al., 1990). Moreover, stress has been linked to increases in infectious illness (Kiecolt-Glaser & Glaser, 1995). Thus, chronic and debilitating
conditions such as panic disorder are likely to compromise immune functioning.
Findings from immune studies of patients with panic disorder are somewhat
mixed, though alterations in immune measures have been noted (Andreoli et al.,
1992; Coplan et al., 1999; Marazziti et al., 1992; Rapaport, 1998; Rapaport &
Stein, 1994). However, we are not aware of studies that have evaluated
whether panic disorder also increases risk for infectious illness.
Fortunately, there are effective means of treating panic disorder. Pharmacological and psychosocial treatments have been found to be efficacious (Wolfe
& Maser, 1994). In particular, cognitive behavioral therapy (CBT) for panic
disorder has been found to be extremely effective in ameliorating panicrelated symptoms using both individual (Barlow, Craske, Cerney, & Klosko,
1989) and group-administered (Telch et al., 1993) treatment. In addition,
patients completing CBT show marked improvements in overall quality of
life (Telch, Schmidt, Jaimez, Jacquin, & Harrington, 1995). For example,
CBT for panic disorder produces marked improvements in familial, social,
and vocational quality-of-life indices (Telch et al., 1995).
Little is known, however, about the effects of treatment on physical health
outcomes in patients with panic disorder. There is some suggestion that pharmacological treatment for panic disorder may positively affect certain cardiac
factors, including heart rate variability (Klein et al., 1995; Tucker et al.,
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1997), as well as cardiac conditions such as mitral valve prolapse (Coplan,
Papp, King, & Gorman, 1992). On the other hand, some pharmacotherapy
interventions appear to adversely affect cardiovascular functioning (Roth et
al., 1992; Taylor & Hayward, 1990). For example, tricyclic antidepressants
appear to increase risk for hypertension (Louie, Louie, & Lannon, 1992). We
could not find studies evaluating the effects of CBT for panic disorder on
nonpsychiatric medical outcomes.
In the present study, we sought to extend previous work on the interplay
between panic disorder and physical health by examining the effects of CBT
for panic disorder on nonpsychiatric medical symptoms. Because CBT has
been found to substantially decrease anxiety symptoms and to improve quality of life, and because high levels of anxiety symptoms appear to be related
to a variety of nonpsychiatric medical problems, it was hypothesized that
treatment-related alleviation of distress would have a significant impact on
physical health symptoms. Specifically, patients completing CBT for panic
disorder were expected to show fewer nonpsychiatric physical symptoms relative to a wait-list control condition. If CBT did produce positive physical health
outcomes, we were also interested in evaluating the role of possible mediating
(e.g., decreased anxiety symptoms) and moderating factors (e.g., presence of a
chronic nonpsychiatric medical condition) affecting this relationship.

Method

Participants
The clinical sample consisted of 46 patients 1 meeting the following criteria: (a) principal DSM-IV (American Psychiatric Association, 1994) Axis I
diagnosis of panic disorder with or without agoraphobia, (b) no change in
medication type or dose during the 8 weeks prior to treatment, (c) no evidence of serious suicide intent, (d) no evidence of current substance abuse,
and (e) no evidence of current or past schizophrenia, bipolar disorder, or
organic mental disorder. Sixty-three percent of the patients were female, with
a mean age of 37.9 years (SD = 12.5). The majority of these patients were
Caucasian (80.4%), married (56.5%), and employed (71.7%). The majority
(71%) received a diagnosis of panic disorder with agoraphobia and 41% had
at least one co-occurring Axis I diagnosis (e.g., 18% major depression, 13%
social anxiety disorder). Approximately half of the sample participants were
medicated during the study (antidepressants 13%, anxiolytics 28%, both antil Some of the patients in the present report took part in a study reported previously (Schmidt
et al., 2000). Administration of the PHRF was initiated toward the end of recruitment for the
Schmidt et al. study such that two groups of patients (n = i2) randomized to the C B T group
and two groups of patients (n = 10) randomized to the delayed treatment group. The present
study combines these patients with an additional four groups of patients who were also randomized to C B T (two groups: n = 10) or delayed treatment (two groups: n = 14). PHRF data were
not reported in the earlier study.
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depressants and anxiolytics 17%). Physical health status and medical morbidity were not selection criteria.
Procedure

Patients were selected from applicants who presented for evaluation at an
academic research center specializing in the assessment and treatment of anxiety disorders. Diagnostic assessment was based on an initial phone screening
interview followed by a face-to-face structured clinical interview using the
SCID-NP (First, Spitzer, Gibbon, & Williams, 1994). Randomly selected videotaped interviews from this sample indicated perfect interrater agreement for a
primary diagnosis of panic disorder (10/10).
After 5 to 7 treatment-eligible patients had completed the baseline assessment, this "group" was assigned to one of two conditions: CBT or a delayed
treatment control. Four groups (n = 22) were assigned to the CBT condition
and received a group-administered cognitive behavioral treatment that consisted of 12 sessions over a 12-week period (cf. Schmidt et al., 2000). Each
session lasted approximately 120 minutes. The treatment protocol included
four major components: (a) education and corrective information regarding
the etiology and maintenance of panic disorder, (b) cognitive therapy techniques aimed at helping the patient to identify and alter faulty appraisals of
threat that contribute to panic occurrence, (c) interoceptive exposure exercises designed to reduce patients' fears of somatic cues through the repeated
exposure to feared bodily sensations, and (d) instruction for conducting in
vivo exposure exercises designed to reduce patients' fears of external situations through repeated exposure to a fear hierarchy. Patients assigned to the
treatment conditions were reassessed immediately following treatment and 6
months after treatment.
Four groups (n = 24) were assigned to the delayed treatment control condition. Patients in this condition were reassessed after 12 weeks and then
received treatment but were not assessed further.
In the active treatment group, treatment integrity was maintained by utilizing a structured and manualized treatment protocol (Safety Maneuver Elimination for Panic Disorder; Schmidt, 1994)that describes the specific
goals and strategies for each session. An independent rater's assessment of
adherence (Young, Beck, & Budenz, 1983) to the treatment protocol has
yielded 100% adherence in a randomly selected set of videotaped treatment
sessions. The first author administered the treatment to all groups. He is a
licensed clinical psychologist with approximately 10 years of experience
with cognitive-behavioral treatment of anxiety disorders. In each group, a
graduate fellow in clinical psychology, a psychiatry resident, or a psychiatrist
acted as co-facilitator.
All 46 subjects who completed the baseline were assessed at posttreatmerit. All of the patients in the active treatment group completed the treatment (completing at least 11 of 12 sessions). Patients were allowed to
reschedule a maximum of 3 sessions with those sessions being rescheduled
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within a few days of the scheduled session. Five of the treated subjects did
not complete the 6-month follow-up (they could not be contacted because of
address changes). Comparisons between those completing treatment and
those lost to follow-up indicated no significant differences in demographics,
physical health parameters, and symptom severity at pretreatment or posttreatment (ps > .05).
Measbtres

A multimodal assessment battery tapping the major clinical dimensions
of panic disorder was administered to all participants at baseline and posttreatment. The same battery was administered to those in the active treatment
group at follow-up. Physical health assessments were made at all assessment periods as well as midway during the treatment or waiting period (Week
6). One of the anxiety measures was also administered during the midtreatmerit assessment. Clinician ratings were made by raters masked to treatment
condition.
Panic Disorder Severity Scale (PDSS). The PDSS is a semistructured interview rating scale for panic disorder (Shear et al., 1997) that includes ratings
of panic frequency and intensity, anticipatory anxiety, avoidance of sensations and situations, and impairment in work and social functioning. Each of
these symptoms is rated on a 0 (none) to 4 (extreme) scale. In the present
report, a composite score was utilized (i.e., average score of all items). The
PDSS has good psychometric properties (Shear et al.). In this sample, two
clinicians making PDSS ratings in a dual interview were found to have high
reliability (average r = .91).
Sheehan Patient-Rated Anxiety Scale (SPRAS). The SPRAS (Sheehan, 1983)
is a widely used self-report scale for assessing the intensity of anxiety symptoms. The SPRAS has demonstrated adequate test-retest reliability (r = .67) and
is highly associated with other measures of anxiety and overall impairment in
panic disorder samples (Schmidt, Staab, Trakowski, & Sammons, 1997). In
the present sample the SPRAS shows high internal consistency (~ = .90).
General Health Survey (GHS). The GHS measures perceptions about health
and includes a checklist for assessing the presence of chronic physical illnesses (e.g., hypertension, asthma, arthritis) and a 6-month history of visits to
health professionals. The GHS has been validated with nonpsychiatric and
psychiatric samples (McHorney, Ware, Lu, & Sherbourne, 1994; McHorney,
Ware, & Raczek, 1993). In the present report, we focus only on reported
physical illnesses.
Physical Health Rating Form (PHRF). The PHRF is an 11-item, clinicianadministered measure that focuses on the occurrence of physical illness during the past 30 days. Because self-report methods focusing on specific, welloperationalized symptoms show better agreement with physician diagnoses
(Orts et al., 1995), patients are given explicit instructions to only endorse specific physical health symptoms arising from medical conditions and to
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exclude symptoms resulting from their anxiety condition. The PHRF covers a
number of related domains, including: (a) disability related to physical illness, (b) frequency of physical health symptoms, and (c) perceived physical
health status. Questions pertaining to the physical health disability score
include: (a) number of days physically ill, (b) number of days missed work or
unable to complete normal daily activities as a result of physical illness, (c)
number of doctor visits, and (d) number of hospitalizations. Items used to
assess frequency of specific symptoms include the number of days experiencing: (a) infections (e.g., flu, common cold), (b) respiratory illness (e.g.,
asthma), (c) gastrointestinal illness (e.g., ulcer), (d) cardiovascular illness
(e.g., MVP), (e) headaches (including migraines), and (f) other illness symptoms. The items targeting specific symptoms were rated on a scale ranging
from 0 days to 5 + days. Finally, the overall perceived physical health rating
was made using the following range: excellent (0), very good (1), good (2),
fair (3), and poor (4). To score the scale, responses to each item were transformed to range from 0 to 5 such that each item was weighted equally, then
summed across the 11 items (¢x = .59).
Results
Description of Nonpsychiatric Medical Comorbidity
and Physical Health Status
Consistent with previous reports, patients with panic disorder reported a
substantial amount of medical comorbidity. Approximately half (56%) of all
patients reported the presence of at least one chronic physical health condition on the GHS at intake. The most frequently endorsed physical conditions
included mitral valve prolapse (17%), asthma (11%), thyroid disease (9%),
high blood pressure (9%), and other (16%; e.g., reflux, Hepatitis C, various
cardiac conditions).

Demographic Comparisons Between Groups
Baseline differences between CBT-treated patients and delayed-treatment
controls were examined using an independent t test for age and chi-square
tests for categorical variables (i.e., sex, ethnicity, marital status, and employment status). Participants in the two groups did not significantly differ on any
of the demographic variables at baseline (ps > .05).
Pretreatment to Posttreatment Effects of CBT
on Anxiety and Physical Health
In order to establish that the treatment significantly decreased both anxiety
symptoms and physical health problems, mixed design analyses of variance
(ANOVAs) were conducted with each of three dependent variables. SPRAS
and PDSS scores represented anxiety symptoms and PHRF scores represented physical health outcomes. Two time points--pretreatment and post-
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TABLE 1
GROUP EFFECTS ON ANXIETY AND HEALTH FROM
PRETREATMENT TO POSTTREATMENT ( A N O V A s )

Pre-Treatment
Group

M

SD

PostTreatment
M

SD

Dependent Variable = SPRAS
CBT
WL

51.09
60.29

27.77
29.29

14.36
43.63

1.87
2.09

0.70
0.81

0.54
t .78

Note.

10.07
11.03

5.24
6.05

4.12
10.41

Time

Interaction

10.23"*
(.19)

68.50***
(.61)

9.67**
(.18)

21.31"**
(.33)

40.36***
(.48)

15.71"**
(.27)

7.31"
(.14)

10.08"*
(.19)

6.64**
(.13)

0.45
0.72

Dependent Variable = PHRF
CBT
WL

Group

l 1.67
18.93

Dependent Variable = PDSS
CBT
WL

F Ratios (Partial ,q2)

3.72
7.18

Sample size was 22 in the CBT group and 24 in the WL group with the exception of one
participant in the WL group missing data on the PDSS. SPRAS = Sheehan PatientRated Anxiety Scale; CBT = cognitive behavioral therapy; W L = wait list; PDSS =
Panic Disorder Severity Scale; PHRF = Physical Health Rating Form.
* p < .05; * * p < .01; * * * p < .001.

treatment--composed a within-subjects factor, while group status--CBT or
wait list (WL)--was the between-subjects factor in each ANOVA. Table 1
shows descriptive statistics for each outcome variable by time and group as
well as the significance and effect sizes of group effects, changes across time,
and the interaction of group by time on each outcome.
As noted in Table 1, significant interaction effects emerged for each outcome variable. In addition, all main effects for group and time were significant. Examination of the marginal means reveals that, for each outcome variable, participants in the CBT group began with lower mean scores than
participants in the WL group. Regardless of group, mean scores on both of
the anxiety measures and the physical health measure decreased across time.
However, participants in the CBT group demonstrated significantly (at least
at the p < .01 level) greater reduction in both anxiety (SPRAS and PDSS)
symptoms and physical health problems (PHRF) than participants in the WL
group, showing the expected benefit of the treatment on both anxiety and
physical health problems. In terms of clinical significance, partial .q2 values
for the interactions suggested that being in the CBT group accounted for 13%
of the change in PHRF scores over time, while accounting for 18% and 27%
of the change in SPRAS and PDSS scores, respectively.
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Mediation and Moderation Analyses
Mediation. To determine whether the reduction in physical health problems attributed to the group treatment may have been mediated by the reduction in anxiety symptoms, we calculated residualized change scores on the
SPRAS from pretreatment to midtreatment, and residualized change scores
on the PHRF from midtreatment to posttreatment. The PDSS was not administered at midtreatment and was therefore excluded from analyses of potential
mediation. The following four conditions for mediation (Baron & Kenny,
1986) would be met if the treatment intervention caused a reduction in anxiety and that reduction in anxiety caused a subsequent reduction in physical
health problems. First, the treatment would significantly predict the initial
change in anxiety. Second, the treatment would also predict the more distal
changes in physical health problems. Third, the initial change in anxiety
would significantly predict the subsequent change in physical health problems when controlling for the effect of treatment, which, finally, would be
substantially reduced compared to its original effect when used alone to predict change in physical health problems.
We conducted two linear regression analyses to evaluate the three conditions
for mediation. The results in Table 2 fail to provide evidence for mediation.
Although the treatment predicted both SPRAS score reductions from pre- to
midtreatment ([3 = - . 4 8 , p < .01) and PHRF score reductions from midto posttreatment (13 = - .42, p < .05), the bottom portion of the table shows
that changes in anxiety (residualized SPRAS scores) failed to predict subsequent changes in PHRF scores at the o~ = .05 level ([3 = .15,p -- .41) after
accounting for the impact of the treatment intervention.

TABLE 2
LINEAR REGRESSION RESULTS FROM ANXIETY MEDIATION ANALYSES

Outcome Variable
Residual SPRAS
Residual PHRF

Note.

Step

Adjusted
R2

Predictors
Included

B

SE B

1
1
2

.20
.15
.14

Group
Group
Group
Residual SPRAS

- 16.08
-3.79
-3.12
.04

5.16
1.45
1.65
.05

-.48**
-.42*
-.34"
.15

"Residual SPRAS" refers to the residual values after regressing SPRAS scores at

midtreatment on SPRAS scores at pretreatment. "Residual PHRF" refers to the residual
values after regressing PHRF scores at posttreatment on PHRF scores at midtreatment.
For the treatment group n = 20 and for the wait-list group n = 15 due to missing data at
the midtreatment collection point. "Group" was coded as follows: cognitive behavioral
treatment = 1, wait list = 0. SPRAS = Sheehan Patient-Rated Anxiety Scale; PHRF =
Physical Health Rating Form.
aApproaches significance,p < .10.
* p < .05; * * p < .01.
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Moderation. We conducted a 2 (within subjects, pretreatment versus posttreatment) by 2 (between subjects, CBT or W L group) by 2 (between subjects, presence versus absence of any chronic illness reported in the GHS)
mixed design ANOVA to investigate whether the observed impact of the
treatment intervention on the reduction of physical health problems depended
upon the presence of a chronic illness (N = 46 for the analysis, with n = 26
participants reporting a chronic illness). In the full-factorial model, the threeway interaction of time by group by chronic illness status was not significant
at the o~ = .05 level, F(1, 42) = .09, p = .76. Therefore, no evidence was
observed for the presence of a chronic illness affecting the impact of the
treatment across time on physical health changes.
Results Through Follow-upfor the CBT Group
Within the CBT group, for which 6-month follow-up data were collected,
changes in physical health (PHRF) as well as changes in anxiety (SPRAS)
were evaluated across all four time points (pretreatment, midtreatment, posttreatment, and 6-month follow-up) using two univariate repeated measures
ANOVAs. Unequal intervals of 5 weeks from pretreatment to midtreatment,
10 weeks from pretreatment to posttreatment, and 36 weeks from pretreatmerit to 6-month follow-up were specified in the model. Linear, quadratic,
and cubic polynomial effects were included. Of the 19 participants who contributed at least some follow-up data, 2 were excluded from the ANOVA
examining PHRF scores over time because of missing data on this measure at
follow-up, and 2 others were excluded from the ANOVA examining SPRAS
scores because of missing data at midtreatment, resulting in n = 17 for each
analysis.
For the polynomial ANOVA examining SPRAS scores over time, overall
F(1.86, 29.83) = 22.97, p < .001, after applying a Huynh-Feldt Epislon correction for violation of the sphericity of variance assumption. This indicated
an overall effect of time on SPRAS scores. Follow-up tests of polynomial
effects showed significant linear, F(1, 16) = 29.74, p < .001, quadratic,
F(1, 16) = 33.26, p < .001, and cubic, F(1, 16) = 6.02, p < .05, effects of
time on SPRAS scores. In the PHRF ANOVA, time effects were also significant overall, F(3, 48) = 23.42, p < .001, as were follow-up tests of linear,
F(1, 16) = 30.64, p < .001, and quadratic, F(1, 16) = 30.41, p < .001,
trends. The cubic effect was not significant, F(1, 16) = 3.78, p = .07. Figure
1 depicts the pattern of findings for both outcome measures.
As a further test of the nature of the significant trends, post hoc t tests of all
pairwise comparisons across time were conducted within each repeated measures ANOVA, applying a Bonferroni adjustment to the resulting significance
levels. For the SPRAS, pretreatment scores differed from scores at each other
time point with at least p < .01 significance. Pretreatment PHRF scores also
differed from scores at each other time point with at least p < .001 significance. The remaining time points did not differ from one another (at the o~ =
.05 level) for either outcome measure. Figure 1 shows the decrease in both
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FIG. 1. Sheehan Patient-Rated Anxiety Scale (SPRAS) scores and Physical Health Rating
Form (PHRF) scores from pretreatment through follow-up in the cognitive behavioral treatment
group (n = 17 for each variable). The double and triple asterisks denote that pretreatment
scores on the SPRAS and PHRF, respectively, differed from scores at the other three time points
with at least p < .01 (SPRAS) and p < .001 (PHRF) significance, respectively, after Bonferroni
correction for all possible comparisons among time points for each variable using t tests. Scores
from midtreatment through follow-up did not differ significantly (p > .05) from each other for
either measure after Bonferroni adjustment.

anxiety and physical health problems from pretreatment to midtreatment that
was maintained throughout the follow-up period.

Discussion
As far as we are aware, this is the first study to evaluate the effects of cognitive behavioral therapy for panic disorder on physical health status. Consistent with many other studies, we have demonstrated that cognitive behavioral
therapy has a significant impact on anxiety symptoms. Of particular interest
here, we also found that cognitive behavioral therapy for panic disorder led to
improvements on physical health status as measured by a composite selfreport rating scale. The fact that significant changes in physical health status
were already evident by midtreatment suggests that CBT can also produce
fairly rapid benefits in relation to physical health.
Interestingly, mediation analyses indicated that changes in anxiety symptoms did not account for the relationship between treatment and the physical
health variables at posttreatment. This would suggest that treatment may be
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affecting physical health tbxough some other mechanism. One possibility is
that general affective distress or depression may be acting as a mediating
variable. This alternative hypothesis is consistent with the fact that CBT has a
notable impact on depression symptoms and that depression has a negative
impact on physical health (Badger, 1998; Druss, Allen, & Bruce, 1998; Judd,
Paulus, Wells, & Rapaport, 1996). To investigate this, we conducted additional
post hoc mediation analyses evaluating changes in depression symptoms as a
potential mediator variable. However, these analyses did not yield convincing
evidence of mediation. Taken together, there is little evidence to suggest that
changes in distress mediated the relationship between CBT and physical health.
An alternative hypothesis is that the changes noted in physical health status
may be a result of changes in psychological or cognitive factors that influence
perceptions of physical health symptoms. Attention or vigilance to bodily
sensations has taken on increased importance in psychological conceptualizations of panic. For example, cognitive models of panic (Barlow, 1988; Clark,
1986) suggest that patients may become vigilant to bodily arousal as a consequence of experiencing panic attacks. Related to this, patients with panic disorder appear to have greater interoceptive accuracy (Ehlers & Breuer, 1992).
In fact, some of our earlier work confirms the fact that patients with panic
disorder are more consciously vigilant to bodily sensations relative to controls and other anxiety disorders (Schmidt, Lerew, & Trakowski, 1997). Conceivably, increased interoceptive acuity or increased attention to bodily cues
may result in increased reporting of physical health symptoms. CBT protocols for panic disorder attempt to target interoceptive processes (e.g., Barlow
& Craske, 2000). Moreover, Schmidt, Lerew, et al. (1997) found that vigilance to bodily sensations was significantly diminished following CBT for
panic disorder. Therefore, patients in the present study may simply be less
aware of physical symptoms that they had previously attributed to a medical
condition. Unfortunately, it is impossible to know whether the treatment actually influenced physical health status or whether the treatment simply altered
perceptions of physical health in the present study. Future work involving
biological parameters is critical to more fully address this issue.
An important consideration regarding the study findings is that nonpsychiatric medical morbidity was based on patient self-report instead of examinations by physicians or laboratory methods. Self-report of physical symptoms
as opposed to health measures obtained from a comprehensive physical examination is an obvious methodological limitation that leaves open the question of
whether patients with panic disorder can reliably report nonpsychiatric medical
symptoms. Despite potential problems, self-reported health symptoms have
been shown to be highly associated with actual health status (LaRue, Bank,
Jarvik, & Hetland, 1979; Mossey & Shapiro, 1982). For example, Bradford,
Graham, and Reinert (1993) found that only 4% of their patient sample had
significant discrepancies between self-reported medical conditions and documented medical histories. Thus, there is reason to believe that the self-report
methodology used in the present study is likely to adequately represent
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physical health symptoms. However, it is recommended that additional work
exploring this relationship should utilize objective physical health measures.
It is also important to consider that subjective or perceived physical health
often provides an accurate gauge of physical health outcomes. A number of
prospective reports have found that perceived health predicts mortality (Idler
& Angel, 1990; Idler & Kasl, 1991; Idler, Kasl, & Lemke, 1990; Kaplan &
Camacho, 1983; Mossey & Shapiro, 1982). In fact, perceived physical health
has been found to predict mortality better than the presence of health problems (Idler & Kasl) or health status assessed by physicians (Mossey & Shapiro). There is also evidence to suggest that perceived health and actual disease severity are independently related to illness-specific anxiety symptoms.
For example, Carr, Lehrer, and Hochron (1995) found that asthma patients'
subjective reports of asthma symptomatology and pulmonary function tests
independently predicted asthma-related panic fear. Thus, perceived physical
health may predict consequential mental and physical health outcomes in
patients with panic disorder.
The limitations of this study need to be considered. The sample size was
modest, particularly for the follow-up analyses. Because some of the findings
amount to accepting the null hypothesis (e.g., lack of moderation effects), it
is possible that the effects are a result of low statistical power. Therefore, replication is certainly warranted. Another limitation of the present report
involved collapsing across many different forms of health problems. Because
of the sample size in the present study, it is not feasible to separately evaluate
each specific medical condition. This type of measurement approach may
obscure potentially salient effects. For example, it may be that CBT differentially affects milder versus more severe medical conditions. It is also important to note that the majority of identified medical problems in the present
study were relatively mild (e.g., MVP, high blood pressure). Other samples
containing a preponderance of more severe medical conditions (e.g., COPD,
heart disease) may produce a different pattern of findings.
The present study points to the complex interplay between panic disorder
and physical health outcomes. Consistent with expectations, data indicate
that CBT affects mental health and physical symptoms. Future work utilizing
biological indicators is needed, however, to more definitively demonstrate
this effect.
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